PeopleBeatingCancer supports an evidence-based integrative approach to cancer care. For most newly diagnosed patients, FDA-approved therapies form the foundation of treatment, while evidence-based complementary therapies may help reduce side effects and improve survivorship.
Click the orange button to the right to learn more.
Endometrial Cancer and Complementary Therapies: CBD, THC, Diet, Curcumin & Green Tea. Can CBD oil, THC, curcumin, green tea, or dietary changes help women diagnosed with endometrial cancer? Which therapies have scientific support, and which remain experimental?
Women diagnosed with endometrial cancer often want to know what they can do beyond surgery, chemotherapy, radiation, or hormonal treatment to improve their health and reduce their risk of recurrence.
Fortunately, research is investigating several complementary approaches, including cannabinoids, nutrition, physical activity, and plant-derived compounds.
However, an important distinction must be made: A therapy that kills cancer cells in a laboratory has not necessarily been shown to treat cancer in people.
As a long-term multiple myeloma survivor, I have spent decades researching evidence-based, non-conventional therapies. My experience has taught me the importance of combining appropriate conventional treatment with complementary approaches that may improve quality of life and long-term health.
Let’s examine the research.
I am a long-term survivor of an incurable blood cancer called multiple myeloma. My research and experience with evidence-based non-conventional therapies are the reason why I have lived in complete remission from my incurable blood cancer since achieving complete remission in early 1999. I have learned that the best way to manage cancer is to combine the best of conventional and evidence-based non-conventional therapies.
Scroll down the page and post a question or a comment if there’s anything you’d like to know about endometrial cancer.
Good luck,
Endometrial cancer begins in the lining of the uterus, called the endometrium. The most common form is endometrioid carcinoma. Many of these tumors are influenced by estrogen signaling and are associated with metabolic risk factors such as obesity and insulin resistance.
Other forms, including serous and clear-cell carcinomas, can behave differently. Modern endometrial cancer treatment increasingly considers:
These characteristics influence treatment choices and recurrence risk. Complementary therapies should be evaluated within this individual clinical context.
Cannabidiol (CBD) is a compound derived from the cannabis plant. Unlike THC, CBD generally does not produce an intoxicating high. Researchers have investigated whether CBD can influence cancer-cell growth and survival.
A 2018 study titled Cannabinoid-induced cell death in endometrial cancer cells: involvement of TRPV1 receptors in apoptosis examined cannabinoid effects on two endometrial cancer cell lines: Ishikawa and Hec50co.
Researchers found that:
These findings suggest that CBD may influence biological mechanisms involved in endometrial cancer-cell survival. However, this research was conducted in laboratory cell models.
It does not demonstrate that CBD oil shrinks endometrial tumors, prevents recurrence, or improves survival in women.
There is currently no clinically validated CBD dose for treating endometrial cancer.
Research: Cannabinoid-induced cell death in endometrial cancer cells
One of the questions I have received as a cancer coach concerns THC and estrogen-sensitive endometrial cancer. Below, a woman with postoperative stage II, grade 1, hormone-receptor-positive endometrial cancer asked whether THC could stimulate cancer progression and whether a CBD-to-THC ratio of 4:1 would be safer.
This is an understandable concern. Some endometrial tumors depend partly on estrogen signaling. Cannabinoids also influence complex biological signaling systems.
However, there is insufficient human clinical evidence to conclude that THC directly causes estrogen-sensitive endometrial cancer to metastasize. Equally important, there is insufficient evidence that THC prevents cancer progression.
A 4:1 ratio means a preparation contains four parts CBD for every one part THC.
No clinical trials have established that this ratio is effective for treating endometrial cancer.
Likewise, recommendations to use CBD oils containing 10%, 20%, or another concentration of cannabinoids are not supported by endometrial cancer treatment trials.
The concentration of cannabinoids in a product is not proof of anticancer effectiveness.
Patients should discuss cannabinoid use with their oncology team, particularly when taking prescription medications or receiving active cancer treatment.
Although cannabinoids have not been established as anticancer treatments, certain cannabinoid medications have a role in supportive oncology. The American Society of Clinical Oncology published a guideline in 2024 reviewing cannabis and cannabinoid use in adults with cancer.
Its recommendations distinguish cancer treatment from symptom management. Selected cannabinoid medicines may be considered for chemotherapy-induced nausea and vomiting that persists despite standard antiemetic therapy.
However, evidence remains limited or inconsistent for many other cancer-related symptoms.
| Symptom | What research suggests |
|---|---|
| Chemotherapy-induced nausea and vomiting | Selected prescription cannabinoid medicines may help when standard antiemetics are inadequate |
| Cancer pain | Evidence is insufficient to recommend routine cannabinoid use |
| Anxiety | Cancer-specific clinical evidence remains limited |
| Sleep problems | Benefits are uncertain |
| Appetite loss | Evidence does not establish a consistent routine benefit |
| Cancer recurrence prevention | No demonstrated benefit |
CBD and THC can also cause adverse effects or interact with medications. Potential concerns include sedation, dizziness, cognitive impairment, liver enzyme abnormalities, and interactions involving drug-metabolizing enzymes.
One of the most interesting nutritional questions concerns sugar consumption and endometrial cancer. A study published in Cancer Epidemiology, Biomarkers & Prevention evaluated sugar-sweetened beverage consumption among 23,039 postmenopausal women in the Iowa Women’s Health Study.
Researchers found that women in the highest category of sugar-sweetened beverage consumption had a 78% higher relative risk of type I endometrial cancer compared with women who did not consume these beverages. The association remained after adjustment for several other risk factors.
However, this was an observational study. It identified an association, not proof that sugar-sweetened beverages directly caused cancer. The 78% figure refers to relative risk, not an absolute 78-percentage-point increase.
Furthermore, the study examined the risk of developing endometrial cancer, not the risk of recurrence after treatment.
Research: Sugar-sweetened beverage intake and endometrial cancer risk
Cancer cells use glucose, but so do healthy cells. Avoiding all sugar or carbohydrates cannot selectively starve a tumor. Instead, the more useful nutritional strategy is to improve overall metabolic health. For many women, this includes limiting sugar-sweetened beverages, choosing fiber-rich carbohydrates, maintaining a healthy weight when appropriate, and managing diabetes or insulin resistance.
These changes may improve general health, even though their effect on endometrial cancer recurrence has not been conclusively established.
Curcumin is a naturally occurring compound found in turmeric. Researchers have investigated curcumin because it can influence several biological pathways associated with inflammation, cell signaling, and cancer-cell behavior.
Laboratory studies involving human endometrial carcinoma cells have reported that curcumin can inhibit processes associated with tumor-cell migration and invasion. One study investigated its influence on matrix metalloproteinases MMP-2 and MMP-9 and the ERK signaling pathway.
These pathways are relevant because they contribute to cellular processes involved in invasion and metastasis. However, the findings do not establish that taking curcumin supplements prevents metastasis or improves survival in women with endometrial cancer.
Laboratory studies are promising, but human clinical trials have not established that curcumin prevents recurrence.
Research: Curcumin suppresses migration and invasion of human endometrial carcinoma cells
Curcumin is scientifically interesting, but there is no established therapeutic dose for preventing endometrial cancer recurrence. Concentrated supplements may also create problems, including medication interactions, gastrointestinal effects, and, in some cases, liver injury. Culinary turmeric and high-dose curcumin supplements should not be treated as equivalent exposures. Women receiving cancer treatment should discuss concentrated curcumin supplements with their oncology team.
Green tea contains polyphenols, including epigallocatechin gallate (EGCG). These compounds have attracted research interest because of their antioxidant and cell-signaling effects.
A systematic review and meta-analysis examining green tea, black tea, and endometrial cancer reported an association between green tea consumption and reduced endometrial cancer risk. However, observational findings can be influenced by lifestyle, dietary, and other differences between study participants. Such research cannot establish that green tea prevents cancer.
Nor does it demonstrate that green tea extract prevents recurrence after endometrial cancer treatment.
Research: Green tea, black tea consumption and risk of endometrial cancer: systematic review and meta-analysis
Drinking ordinary green tea and taking concentrated EGCG supplements are different interventions. Green tea can be included in a balanced diet for many people. Concentrated green tea extracts, however, have been associated with liver injury and may interact with medications. There is no established EGCG supplement dose for treating or preventing endometrial cancer.
Compared with experimental supplements, nutrition and metabolic health offer more established opportunities to support overall survivorship. Endometrial cancer is strongly associated with metabolic factors, including obesity and insulin resistance, particularly for endometrioid cancers.
An evidence-informed dietary pattern emphasizes:
A Mediterranean-style eating pattern is one practical way to achieve these goals.
For women who are overweight, gradual and sustainable weight management may improve blood pressure, insulin resistance, diabetes control, and cardiovascular health. However, weight loss should be individualized. Women experiencing treatment-related weight loss, poor appetite, or muscle loss may need nutritional rehabilitation rather than calorie restriction.
No particular diet has been conclusively proven to prevent endometrial cancer recurrence.
Research: American Cancer Society: Living as an Endometrial Cancer Survivor
Physical activity is one of the better-supported complementary strategies for improving health and quality of life after cancer.
Potential benefits include:
Some observational research also suggests that physically active endometrial cancer survivors may experience improved survival outcomes. However, observational associations do not prove that exercise directly prevents recurrence.
Women recovering from surgery or undergoing treatment should adapt activity to their physical condition and medical restrictions. Walking, resistance training, and other appropriate movement can all be useful.
For a broader discussion of the practical demands of diagnosis and treatment, read
Endometrial Cancer Time Burden: What Patients Need to Know.
The following table separates biological plausibility, clinical evidence, and practical applications.
| Therapy or intervention | Evidence rating | Interpretation |
|---|---|---|
| CBD-induced endometrial cancer-cell death | Preclinical | Laboratory activity; no established patient benefit |
| CBD to prevent recurrence | Insufficient | No demonstrated clinical effectiveness |
| THC to treat endometrial cancer | Insufficient | No validated anticancer benefit |
| THC causing hormone-sensitive cancer progression | Insufficient | No reliable human evidence establishing causation |
| 4:1 CBD-to-THC ratio | Insufficient | No validated anticancer ratio |
| Prescription cannabinoids for refractory chemotherapy nausea | Moderate, condition-specific | May be considered as supportive care |
| Curcumin to prevent endometrial cancer recurrence | Preclinical/insufficient | Laboratory findings do not establish clinical benefit |
| Green tea for primary endometrial cancer prevention | Limited observational | Possible association, not proof of prevention |
| EGCG supplements to prevent recurrence | Insufficient | No established clinical benefit |
| Limiting sugar-sweetened beverages | Observational for cancer risk; stronger for metabolic health | Sensible dietary strategy, but recurrence benefit unproven |
| Physical activity for physical function and fatigue | Strong supportive-care evidence | Benefits overall health and survivorship |
| Mediterranean-style dietary pattern | Supportive general-health evidence | Reasonable dietary approach; recurrence benefit unproven |
How to interpret these ratings: Strong or moderate evidence refers to a defined outcome, not necessarily cancer control. Preclinical evidence comes from laboratory or animal research. Observational evidence identifies associations but cannot establish causation. Insufficient evidence means that reliable conclusions about the claimed benefit or harm cannot currently be drawn.
This is the most important question for many survivors. The answer is that no CBD preparation, THC product, curcumin supplement, green tea extract, or special diet has been conclusively shown to prevent endometrial cancer recurrence.
That does not mean complementary therapies have no value. Nutrition, exercise, symptom management, rehabilitation, and psychological support can contribute meaningfully to recovery and quality of life.
However, the risk of recurrence depends heavily on the original cancer’s stage, grade, histology, molecular characteristics, and treatment. Survivors should continue recommended follow-up care and promptly report concerning symptoms, particularly new vaginal bleeding, persistent pelvic pain, or other unexplained changes.
If you are considering complementary therapies after an endometrial cancer diagnosis, ask:
No clinical evidence establishes that CBD oil cures endometrial cancer. Laboratory findings remain preliminary.
There is insufficient human evidence to establish that THC accelerates estrogen-sensitive endometrial cancer progression. Its safety for an individual tumor is also not established.
No specific cannabinoid ratio has been clinically validated for treating endometrial cancer.
Some observational studies associate higher added-sugar or sugar-sweetened beverage intake with increased endometrial cancer risk. These studies do not establish that eating sugar directly causes cancer.
Green tea can be part of a healthy dietary pattern. Some population studies suggest a possible association with lower endometrial cancer risk, but recurrence prevention has not been demonstrated.
For overall survivorship health, appropriately tailored physical activity, adequate nutrition, rehabilitation, and evidence-based symptom management have stronger clinical support than cannabinoids or concentrated botanical supplements.
CBD, THC, curcumin, and green tea are all subjects of scientific investigation. Some laboratory studies have identified potentially useful biological effects, particularly involving CBD and curcumin. But scientific promise is not the same as clinical proof.
For women diagnosed with endometrial cancer, I believe the most reasonable integrative approach is to combine appropriate conventional treatment with evidence-based strategies that support physical health, treatment tolerance, and quality of life.
As a long-term multiple myeloma survivor, I understand why cancer patients want to explore every reasonable option.
My goal at PeopleBeatingCancer is to help patients distinguish between therapies that are scientifically promising, therapies that have demonstrated clinical benefits, and therapies whose risks or effectiveness remain uncertain.
Editorial disclosure: PeopleBeatingCancer provides educational information about conventional and complementary cancer therapies. Laboratory findings, observational associations, and patient experiences should not be interpreted as proof of clinical effectiveness. Supplements and cannabinoids may cause adverse effects or interact with cancer treatment. Treatment decisions should be discussed with qualified oncology professionals.
Dear Cancer Coach,
I am post-operative stage 2 endometrial cancer, estrogen hormone positive, grade 1. I have read that THC can cause hormonally driven cancers to spread. I have seen conflicting advice about this. One site recommended a 4:1 CBD-to-THC ratio. Do you agree with this?
I may need a coach.
Karen
Hi Karen,
Thank you for reaching out. Your questions are important, particularly because your cancer is hormone-receptor positive. The short answer is that CBD has demonstrated interesting anticancer effects in laboratory research, but we do not have convincing clinical evidence that CBD oil treats endometrial cancer, prevents recurrence, or improves survival.
Likewise, there is insufficient clinical evidence to conclude that THC necessarily causes estrogen-sensitive endometrial cancer to spread. There is also no established CBD-to-THC ratio for treating endometrial cancer.
Let’s examine the research.
A 2018 study published in the Journal of Physiology and Biochemistry investigated the effects of cannabinoids on endometrial cancer cells.
Researchers studied two endometrial cancer cell lines, Ishikawa and Hec50co.
They found that:
These findings suggest that CBD and the endocannabinoid system deserve further investigation. However, this was an in vitro study, meaning experiments were performed on cancer cells in a laboratory. It did not establish that CBD oil shrinks endometrial tumors, reduces recurrence, or improves survival in women. Nor does it establish a safe or effective dose.
TRPV1 is a receptor involved in several cellular signaling processes. Researchers are interested in whether activating this receptor could influence cancer-cell survival. The 2018 study suggests that CBD-related TRPV1 signaling may promote apoptosis in certain endometrial cancer cells. This provides a biological rationale for additional research—not a clinically validated cancer treatment.
This is the central concern in Karen’s question. Many endometrioid endometrial cancers are influenced by estrogen signaling. Consequently, patients understandably want to avoid substances that might stimulate hormone-sensitive tumor growth.
However, cannabinoids interact with multiple receptors and signaling pathways. Their effects can vary according to the compound, concentration, cancer type, and experimental conditions.
At present:
My recommendation: Do not assume THC is either protective or harmful to your specific cancer without stronger clinical evidence.For hormone-receptor-positive endometrial cancer, treatment decisions should be guided by established clinical factors, including stage, grade, histology, molecular classification, and other pathology findings.
There is no validated CBD-to-THC ratio for treating endometrial cancer. A 4:1 preparation contains four parts CBD for every one part THC. For example, a preparation containing 20 mg CBD and 5 mg THC has a 4:1 ratio. But the ratio alone tells us little about anticancer effectiveness.
Other important considerations include:
A CBD-rich preparation may produce different psychoactive effects from a THC-dominant preparation, but that does not mean it provides better cancer control. The earlier recommendation that CBD oil should contain 10–20% cannabinoids is also not supported by clinical evidence for endometrial cancer.
A product’s concentration describes how much cannabinoid it contains, not whether that concentration is therapeutically effective.
In 2024, the American Society of Clinical Oncology published an evidence-based guideline addressing cannabis and cannabinoid use in adults with cancer.
Research: Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline
The guideline reached several important conclusions. Cannabinoids should not replace conventional cancer treatment. There is insufficient evidence that CBD, THC, or cannabis products can reliably control cancer growth in humans. Certain cannabinoids may help refractory chemotherapy-induced nausea and vomiting. Dronabinol, nabilone, or a quality-controlled oral THC preparation may be considered as additions to appropriate antiemetic treatment when nausea and vomiting persist despite standard therapy.
Evidence for other symptoms remains uncertain. Research has not established consistent benefits for cancer pain, sleep, anxiety, appetite, or overall quality of life. High-dose CBD deserves particular caution.
ASCO recommends against using oral CBD at doses of 300 mg or more daily for symptom management outside clinical trials because benefits have not been demonstrated and liver enzyme abnormalities may occur. These recommendations are relevant to women with endometrial cancer who are considering cannabinoids as complementary therapy.
Although CBD has not been established as an endometrial cancer treatment, cannabinoids are being investigated for supportive care.
| Symptom | Current evidence | Practical interpretation |
|---|---|---|
| Chemotherapy nausea | Moderate for selected THC-based medicines; low for THC extracts | May help when standard antiemetics fail |
| Cancer pain | Insufficient evidence for routine use | Not a proven substitute for pain management |
| Anxiety | Very limited cancer-specific evidence | Benefits remain uncertain |
| Sleep difficulties | Inconsistent evidence | Not established as an effective cancer-related sleep treatment |
| Poor appetite | Limited and inconsistent evidence | No established routine benefit |
| Cancer recurrence prevention | No convincing clinical evidence | CBD should not be used for this purpose |
Patients considering cannabinoids for symptom management should discuss their medications and treatment plan with their oncology team. CBD can affect drug-metabolizing enzymes, potentially altering exposure to some prescription medications.
THC can also cause dizziness, sedation, impaired coordination, and cognitive changes. Additional caution is appropriate during chemotherapy, immunotherapy, and when taking sedatives, anticoagulants, or medications metabolized by the liver.
Karen’s question also raises a broader issue. Can evidence-based complementary therapies improve the experience of endometrial cancer treatment and survivorship? I believe this is an important area for patients to explore.
However, we must distinguish therapies supported by human clinical research from compounds that have demonstrated only laboratory activity.
Curcumin, a biologically active compound found in turmeric, has been studied for its effects on cancer-related signaling pathways.
Research: Curcumin suppresses migration and invasion of human endometrial carcinoma cells
Laboratory experiments suggest that curcumin can influence mechanisms associated with endometrial cancer-cell migration and invasion. These findings are interesting, but they do not establish that curcumin supplements prevent metastasis or improve survival. Curcumin supplements may also interact with medications and are not universally free of adverse effects.
Endometrial cancer is closely associated with metabolic factors, including obesity and insulin resistance. For survivors, maintaining good metabolic health is an important part of overall care.
Reasonable strategies include:
These strategies support general health and may improve survivorship outcomes, although no particular diet has been proven to prevent endometrial cancer recurrence.
Regular physical activity can improve physical functioning, fatigue, metabolic health, and quality of life in many cancer survivors.
Women recovering from endometrial cancer surgery should begin with activities appropriate to their recovery and medical restrictions. Even modest, consistent movement can be beneficial.
For additional information about the practical demands of treatment and recovery, read Endometrial Cancer Time Burden: What Patients Need to Know.
The following table separates scientific plausibility from demonstrated clinical benefit.
| Therapy or claim | Evidence rating | Interpretation |
|---|---|---|
| CBD induces apoptosis in endometrial cancer cells | Preclinical evidence | Demonstrated in selected laboratory cell models |
| CBD reduces endometrial cancer recurrence | Insufficient evidence | No established clinical benefit |
| THC accelerates estrogen-sensitive endometrial cancer | Insufficient evidence | No reliable human evidence establishing this effect |
| A 4:1 CBD-to-THC ratio treats endometrial cancer | Insufficient evidence | No validated anticancer ratio |
| Selected cannabinoids for refractory chemotherapy nausea | Moderate to low clinical evidence | Conditional supportive-care use |
| Exercise for physical function and quality of life | Strong supportive-care evidence | Benefits overall survivorship health |
| Curcumin as an endometrial cancer treatment | Preclinical evidence | Human efficacy remains unproven |
How to interpret these ratings: Preclinical evidence identifies promising biological mechanisms but cannot establish clinical effectiveness. Moderate or strong supportive-care evidence may support symptom management without demonstrating an anticancer effect. Insufficient evidence means reliable conclusions cannot currently be drawn.
For a woman with hormone-sensitive endometrial cancer, I would recommend asking:
For a patient with stage II endometrial cancer, understanding the recommended postoperative treatment plan is especially important. Depending on individual risk factors, surgery may be followed by radiation, chemotherapy, or other treatment. CBD should not replace those discussions.
CBD has reduced cancer-cell viability in laboratory studies, but there is no convincing clinical evidence that CBD oil shrinks endometrial tumors in patients.
Cannabinoids may influence hormonal signaling in experimental systems, but available evidence does not establish that ordinary THC exposure increases estrogen in a way that predictably promotes endometrial cancer progression.
CBD generally lacks THC’s intoxicating effects, but that does not establish that it is safer for a particular hormone-sensitive tumor. Both substances have potential adverse effects and drug interactions.
That decision should be discussed with your surgeon or oncology team, especially during postoperative recovery or while taking pain medications, sedatives, or anticoagulants.
There is no convincing human clinical evidence that CBD prevents recurrence.
CBD and other cannabinoids remain interesting subjects for endometrial cancer research. Laboratory studies have identified biological mechanisms through which CBD may influence endometrial cancer cells, including TRPV1 signaling and apoptosis.
But laboratory activity is not proof of clinical benefit. For patients like Karen, I would emphasize three principles:
As a long-term multiple myeloma survivor, I have spent decades learning about conventional and non-conventional cancer therapies. My experience has convinced me that patients benefit from understanding their options and participating actively in treatment decisions.
But personal experience and promising laboratory studies should not be confused with clinical proof. If you have questions about endometrial cancer, CBD, THC, or complementary therapies, please leave a comment below.
Medical disclaimer: This article provides educational information, not individualized medical advice. Cannabinoids, supplements, and complementary therapies should be discussed with qualified clinicians, particularly during active cancer treatment.
“The purpose of the present study was to characterize cannabinoid elements and evaluate the effect of cannabinoids in endometrial cancer cell viability…
These data indicate that cannabinoids modulate endometrial cancer cell death. Selective targeting of TPRV1 by AEA, CBD, or other stable analogues may be an attractive research area for the treatment of estrogen-dependent endometrial carcinoma. Our data further support the evaluation of CBD and CBD-rich extracts for the potential treatment of endometrial cancer, particularly, that has become non-responsive to common therapies…”
“The purpose of this study was to detect the anti-metastatic effects of curcumin and the associated mechanism(s) in EC. Based on assays carried out in EC cell lines, it was observed that curcumin inhibited EC cell migration and invasion in vitro…
Combined treatment with ERK inhibitor U0126 and curcumin resulted in a synergistic reduction in MMP-2/-9 expression; the invasive capabilities of HEC-1B cells were also inhibited. In conclusion, curcumin inhibits tumor cell migration and invasion by reducing the expression and activity of MMP-2/9 via the suppression of the ERK signaling pathway, suggesting that curcumin is a potential therapeutic agent for EC…”
Endometrial Cancer and Complementary Therapies Endometrial Cancer and Complementary Therapies Endometrial Cancer and Complementary Therapies Endometrial Cancer and Complementary Therapies Endometrial Cancer and Complementary Therapies Endometrial Cancer and Complementary Therapies